$heff's $tation of $tocks & $olid DD

[pmony5]

TTNP just out on Briefing.. Titan Pharma initiated with a Market Perform at Brinson Patrick; tgt $5 (2.04 +0.17)

Brinson Patrick initiates TTNP with a Market Perform and price target of $5. They believe many of the chronic patients will switch to Probuphine, but their models only assume a single-digit share. They believe the FDA has every reason under the sun to approve Probuphine. Probuphine's clinical package is impressive, they have no doubt Probuphine effectively reduces an addicts drug abuse habits...based on the results of Probuphine's Phase 3 trials. An FDA Advisory Committee will release their briefing documents March 19th that will give investors insights into the FDA's April 30th PDUFA decision. They believe the Advisory Committee will be a platform for drug abuse experts to pound the table for this treatment and they encourage investors to buy TTNP shares ahead of that event.